anti- DAXX antibody

Este producto es parte de DAXX - Death-associated protein 6
anti- DAXX antibody

Pida mas información

935106861

info@markelab.com

Precio

Precio a consultar

Antibody anti-DAXX

proveedor

FineTest

reference

FNab02249

Tested Applications

ELISA, WB

reactivity

human,mouse

status

RUO

clonality

polyclonal

Descripción

Transcription corepressor known to repress transcriptional potential of several sumoylated transcription factors. Down-regulates basal and activated transcription. Its transcription repressor activity is modulated by recruiting it to subnuclear compartments like the nucleolus or PML/POD/ND10 nuclear bodies through interactions with MCSR1 and PML, respectively. Seems to regulate transcription in PML/POD/ND10 nuclear bodies together with PML and may influence TNFRSF6-dependent apoptosis thereby. Inhibits transcriptional activation of PAX3 and ETS1 through direct protein-protein interactions. Modulates PAX5 activity; the function seems to involve CREBBP. Acts as an adapter protein in a MDM2-DAXX-USP7 complex by regulating the RING-finger E3 ligase MDM2 ubiquitination activity. Under non-stress condition, in association with the deubiquitinating USP7, prevents MDM2 self-ubiquitination and enhances the intrinsic E3 ligase activity of MDM2 towards TP53, thereby promoting TP53 ubiquitination and subsequent proteasomal degradation. Upon DNA damage, its association with MDM2 and USP7 is disrupted, resulting in increased MDM2 autoubiquitination and consequently, MDM2 degradation, which leads to TP53 stabilization. Acts as histone chaperone that facilitates deposition of histone H3.3. Acts as targeting component of the chromatin remodeling complex ATRX:DAXX which has ATP-dependent DNA translocase activity and catalyzes the replication-independent deposition of histone H3.3 in pericentric DNA repeats outside S-phase and telomeres, and the in vitro remodeling of H3.3-containing nucleosomes. Does not affect the ATPase activity of ATRX but alleviates its transcription repression activity. Upon neuronal activation associates with regulatory elements of selected immediate early genes where it promotes deposition of histone H3.3 which may be linked to transcriptional induction of these genes. Required for the recruitment of histone H3.3:H4 dimers to PML-nuclear bodies(PML-NBs); the process is independent of ATRX and facilitated by ASF1A; PML-NBs are suggested to function as regulatory sites for the incorporation of newly synthesized histone H3.3 into chromatin. In case of overexpression of centromeric histone variant CENPA(as found in various tumors) is involved in its mislocalization to chromosomes; the ectopic localization involves a heterotypic tetramer containing CENPA, and histones H3.3 and H4 and decreases binding of CTCF to chromatin. Proposed to mediate activation of the JNK pathway and apoptosis via MAP3K5 in response to signaling from TNFRSF6 and TGFBR2. Interaction with HSPB1/HSP27 may prevent interaction with TNFRSF6 and MAP3K5 and block DAXX-mediated apoptosis. In contrast, in lymphoid cells JNC activation and TNFRSF6-mediated apoptosis may not involve DAXX. Shows restriction activity towards human cytomegalovirus(HCMV).


Background

Death-Associated Protein 6 (DAXX) is a multifunctional protein involved in apoptosis regulation, transcriptional control, and chromatin remodeling. Initially identified as a Fas-binding protein, DAXX can mediate apoptotic signals in response to Fas receptor activation, playing a role in programmed cell death. In addition to its role in apoptosis, DAXX functions as a transcriptional co-repressor, interacting with various transcription factors to modulate gene expression. DAXX is also a key component of the chromatin remodeling machinery, where it interacts with histone chaperones and contributes to histone deposition and nucleosome assembly. It is localized to promyelocytic leukemia nuclear bodies (PML-NBs) and telomeres, where it participates in DNA damage responses and telomere maintenance. Dysregulation of DAXX is linked to cancer, as it can act as a tumor suppressor or promoter depending on the cellular context. Mutations in DAXX are frequently observed in pancreatic neuroendocrine tumors and other cancers, where they contribute to genomic instability and altered gene expression. DAXX is being investigated as a therapeutic target due to its diverse roles in apoptosis, chromatin dynamics, and tumorigenesis.

Características del producto

category

Primary Antibodies


clonality

polyclonal


reactivity

human,mouse


immunogen target

death-domain associated protein


host

Rabbit


isotype

IgG


conjugation

Unconjugated


form

liquid


tested applications

ELISA, WB


observerd MW

120 kDa, 70 kDa


purity

≥95% as determined by SDS-PAGE


purification

Immunogen affinity purified


recommended dilution

WB: 1:500-1:2000


size 1

100µg


storage

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)


or code

DAXX


alias

DAXX, BING2, DAP6, EAP1, death-domain associated protein, death domain associated protein, SMIM40


note

This product is for research use only.


Quizá le pueda interesar

anti- DAXX antibody

anti- DAXX antibody

proveedor

FineTest

reference

FNab02249

Tested Applications

ELISA, WB

reactivity

human,mouse

status

RUO

clonality

polyclonal

Transcription corepressor known to repress transcriptional potential of several sumoylated transcription factors. Down-r...

Precio a consultar

Ver más

Death Domain Associated Protein / DAP6 (DAXX) Antibody

Death Domain Associated Protein / DAP6 (DAXX) Antibody

proveedor

Abbexa

reference

abx010630

Tested Applications

ELISA, WB, IF/ICC, FCM

reactivity

Human

status

RUO

clonality

Monoclonal

Daxx is a transcriptional co-regulatory protein. Proposed to mediate activation of the JNK pathway and apoptosis via ASK...

383.5€ (100 µl)

Ver más

DAXX (pS213) Antibody

DAXX (pS213) Antibody

proveedor

Abbexa

reference

abx031856

Tested Applications

ELISA, WB, IHC

reactivity

Human

status

RUO

clonality

Polyclonal

DAXX is proposed to mediate activation of the JNK pathway and apoptosis via MAP3K5 in response to signaling from TNFRSF6...

292.5€ (80 µl)

Ver más